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Abstract Fecal microbiota transplantation (FMT) has
attracted great interest in recent years, largely due to
the global Clostridium difficile infection (CDI) epidemic
and major advances in metagenomic sequencing of the
gastrointestinal (GI) microbiota, with growing under-
standing of its structure and function. FMT is now rec-
ommended as the most effective therapy for relapsing
CDI and, with further refinement, may even be used in
“first-time” CDI. There is interest also in other condi-
tions related to GI dysbiosis—for example, inflammatory
bowel disease, irritable bowel syndrome, obesity, and
diabetes mellitus—although quality evidence is at present
lacking. A few trials are now underway in FMT for ulcerative
colitis. Many unanswered questions remain, including FMT
methodology—for example, optimal route of administration,
what makes a “good donor,” safety issues, and long-term
effects of FMT.
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Introduction
Fecal microbiota transplantation (FMT) is the introduction of
a fecal suspension derived from a healthy donor into the
gastrointestinal (GI) tract of a diseased individual. While
not a new therapeutic concept [1, 2], it has, over the last
few years, experienced a significant growth in interest, with
an evolving methodology and clinical indications largely due
to two factors: (1) the global CDI epidemic and (2) a growing
appreciation of the complexity of the GI microbiome and its
active role in health and disease. FMT is no longer consid-
ered an “alternative,” last-resort medical practice but, rather,
is now gaining mainstream acceptance as a valuable, al-
though still poorly understood, therapy with biological plau-
sibility. This is reflected in the increasing number of scien-
tific publications related to FMT. In this review, we will
summarize the latest evidence, indications, and methods of
administering FMT, and provide some insight into future
directions and therapeutic potentials.
The Gastrointestinal Microbiota
The human GI microbiota is considered a tissue, not an
organ, and is used in FMT to implant in a recipient’s GI
tract. To understand the utility of FMT, it is first necessary to
appreciate the compositional complexity of the GI
microbiota, along with its associated functional implications.
There are about 1014 bacterial cells in our body—10 times
more than the roughly 1013 human cells [3]—and most of
these bacterial cells reside in the GI tract. Only about 30 % of
the GI microbiota is detectable by culture-based techniques
[4]. Detailed sequencing studies suggest that 15,000–36,000
different bacterial species are known to inhabit the human GI
tract [5, 6], with each individual hosting roughly 500–1,500
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species, although only a small subset of these are prevalent.
Recent metagenomic sequencing analysis established a hu-
man gut microbial gene catalogue, identifying 3.3 million
nonredundant microbial genes, approximately 150 times
larger than the entire human gene complement [7]. The GI
microbiota and their genetic products exist in a complex, but
balanced, homeostasis and have important roles in nutrition,
energy metabolism, host defense, and immune system de-
velopment [8–10, 11••]. Dysbiosis, or abnormal composi-
tional disturbance of this homeostasis, can be associated with
various disease states. Such conditions are potentially ame-
nable to therapy with FMT to correct these changes.
Current Indications
Clostridium difficile Infection
FMT is most widely used, and now recommended, in the
indication of Clostridium difficile infection (CDI) [12••].
CDI is an ideal condition for FMT, since it is primarily a
GI dysbiosis with Clostridium difficile overgrowth. CDI has
traditionally yet counterintuitively been treated with antibi-
otics such as metronidazole, vancomycin, and, more recent-
ly, fidaxomicin or rifaximin. However, antibiotic therapy
results in further microbiota damage and in recurrence rates
of at least 20 %, which rise with each subsequent CDI
episode [13–15]. Furthermore, antibiotics do not correct the
abnormal microbiome but, rather, potentiate the problem.
Conversely, FMT corrects the imbalanced microbiota that
underlies CDI pathogenesis by providing the patient with a
healthy microbiota that has a structural and functional ho-
meostasis derived from a suitable donor.
Historically, FMT has been offered only in a few special-
ized centers globally, but in the last few years, there has been
growing use of FMT, with numerous publications frommany
international sites demonstrating efficacy in CDI. Most of
these have been uncontrolled, but they have all reported high
success rates of around 90 % or more [16–21]. The global
experience of FMT in CDI is now in excess of 500 patients.
The first randomized controlled trial involving FMT for
relapsing CDI was published earlier this year and demonstrated
vast superiority of FMT over traditional antibiotic therapy
[22••]. FMT had a success rate of 81 % following a single
naso-duodenal infusion and 94 % following a second infusion,
while vancomycin 500 mg qid for 2 weeks with or without
bowel lavage had only 23 %–31 % efficacy. After FMT, there
was increased bacterial diversity, with increases in
Bacteroidetes species, Clostridia class IV and XIVa, and de-
creased Proteobacteria. No significant adverse events were
noted other than mild infusion-related diarrhea and discomfort.
The trial was stopped early after interim analysis, given the
difference between treatments and success of FMT. This study
provided the highest-level evidence for superiority of FMTover
current optimal care antibiotics. It also shifted FMT into the
focus of mainstream medicine, soon followed by the American
College of Gastroenterology formally recommending FMT in
its Guidelines for Relapsing CDI (R-CDI) [12••]. Future re-
search in FMT for CDI should now shift to refining the
microbiota product, administration methodology, luminal ef-
fects of FMT on the resident flora, and assessing safety. An
important area to study will be the use of FMT in severe and
fulminant CDI and in certain high-risk patient groups, such as
the profoundly immunosuppressed.
Another area of FMT use is the treatment of CDI coinfec-
tion in inflammatory bowel disease (IBD). The original
report of this approach included 6 patients, 4 with UC and
2 with Crohn’s disease (CD). All were treated successfully
with improvement in colitis symptoms [23]. Other cases of
successful treatment have recently been reviewed by
Anderson et al. [24•], who identified eight case series/reports
with a total of 15 patients treated with FMT for CDI
coinfecting IBD (9 UC, 6 CD). All had resolution of CDI,
with 86 % demonstrating improved response to IBD medi-
cations. Reddy et al. [25] adds further to our total experience
in this area. The coexistence with IBD may require addition-
al infusions to ensure successful CDI eradication [17].
Current Methodology
FMT transplant material (TM), medically classified as a
human tissue, is derived from healthy donors, with no risk
factors for transmissible diseases or any issues that may alter
the cellular composition, particularly antibiotic use.
Published international guidelines by the FMT Working
Group outline in detail the FMT donor selection criteria
and screening tests [26].
Initially, patients identified their own donors selected
from family or friends. Subsequently, some institutions of-
fered the option of an anonymous donor(s). This shifts the
burden of donor identification from the patient, creates a
pool of tested healthy donors with a track record of cure,
and also avoids donors with shared genetic or environmental
susceptibilities to the recipient. Donor stool is delivered to
the institution within a few hours of passage to undergo (1)
dilution, generally with normal saline, (2) homogenization
with a blender to achieve a liquid slurry, and then (3) filtra-
tion to remove particulate matter to facilitate administration.
Most institutions utilize fresh feces, necessitating collec-
tion and processing on the day of planned FMT. Hamilton
et al. [17] have adopted an approach of using highly filtered
human microbiota mixed with a cryoprotectant and then
frozen for storage at −80 °C until required for use. This
processing removes the fecal smell and reduces the volume
of the filtrate. Use of such a standardized, purified tissue has
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been shown to have equivalent clinical efficacy in CDI to
that of fresh, partly filtered feces. Furthermore, detailed
microbiological studies with 16S rRNA gene sequencing
demonstrated stable “engraftment” or “implantation” of do-
nor microbiota with the frozen product [27•], with dramatic
shifts in recipient gut microbial communities noted after
transplantation.
The route of the TM administration varies considerably
between institutions and can be naso-duodenal, transcolo-
noscopic, or enema based. Some practical issues arise related
to naso-duodenal administration. Some patients may not find
it “palatable” to have fecal material via the upper gut; the
occasional complication, such as vomiting, would be
avoided with lower GI infusion, and infusion of lower colonic
microbiota into the upper GI tract seems unphysiological and
may disturb the local microbial balance. Colonoscopy offers
the advantage of allowing direct assessment of the colonic
mucosa for disease severity and exclusion of coexistent
pathology. Additionally, the use of bowel preparation theoret-
ically may assist in “flushing out” the abnormal host
microbiota and facilitate “implantation” of the donor
microbiota. Enema administration is effective, cheap, and safe
and carries less procedural or institutional admission costs. A
systematic review of 325 cases of FMT for CDI suggested a
lower success rate for upper gut administration (76 %), as
compared with colonoscopy (89 %) and enema (95 %) ad-
ministration [28]. A recent analysis had similar findings, with
a trend toward higher CDI resolution rates with lower GI,
rather than upper GI, administration (91 % vs. 82 %) [29],
although no head-to-head comparison has yet been
performed.
Future Indications
Ulcerative Colitis: Curable in Some
Increasing evidence supports a microbial influence in the
pathogenesis of IBD, likely due to an inappropriate immune
response toward a component or components of the
microbiota [30, 31]. Evidence for a specific pathogen caus-
ing IBD is inconclusive, but there is literature suggesting
reduced diversity of luminal microbiota in IBD, with distinct
compositional and functional changes. We know that certain
bacterial species can be depleted in various disorders. In
CDI, reduced Bacteroidetes and Firmicutes have been
shown to be replenished after FMT, albeit their activity in
clearing CDI is unknown [32]. In IBD, both Bacteroidetes
and Firmicutes are deficient [5], and mouse models suggest
that such bacteria may play an important role activating
regulatory T cells [33–35].
The initial rationale for use of FMT in IBD was that if
C. difficile causes colitis with reduced microbial diversity and
if FMTcan reverse this, a similar treatment could be applied to
ulcerative colitis (UC). With this in mind, the lead author
treated his first UC patient in early 1988, with others soon
following, and FMT treatment in 55 patients with various GI
disorders was reported in 1989 [36]. Later, the group detailed
longer-term follow-up in six UC cases [37]. Today, some
25 years later, the first patient remains asymptomatic with
normal histology. In January 1989, Bennet and Brinkman
published a case of non-CDI UC treated successfully using
FMT [38]. Bennet stopped his own colitis using large-volume
donor enemas 6 months prior. Before FMT, his severe colitis
was continuously active for 7 years. At 3 months post-FMT,
he was asymptomatic and on no UC therapy for the first time
in 11 years. These case reports and others since suggest that
UC is curable in a subgroup of patients.
Anderson et al. [24•] summarized various case reports
published on FMT in IBD that had promising findings.
Remission was reported in 15 of 24 patients (63 %), cessa-
tion of IBDmedications in 13/17 (76 %), and reduction of GI
symptoms in 19/25 (76 %). Similarly, Brandt confirmed the
activity of FMT in his experience with treating UC [25, 39].
Recently, the lead author’s group reviewed their UC cases
treated over the last 24 years [40] and discovered an inter-
esting phenomenon. It seems that although initial FMT may
not immediately cure UC, as happens with CDI, over many
months to years, the implanted microbiota appears to pro-
gressively transform the inflamed UC mucosa to normal,
histologically uninflamed mucosa. Twelve of 21 patients
(57 %) who had repeat colonoscopy at a mean of 33 months
(range 1–198 months) demonstrated complete mucosal
healing with normal endoscopic appearance and no histolog-
ical inflammation (Fig. 1).
A phase 1 trial has just been completed in 10 children and
young adults with mild to moderate UC [41]. Patients re-
ceived 5 days of FMTand were then followed up. At 1-week
post-FMT, 33 % achieved clinical remission, and 78 % had a
clinical response, with 67%maintaining response at 4weeks.
This confirms that FMT response in UC/IBD is not as pre-
dictable as it is in CDI. There is currently significant interest
in this area, with at least four registered trials being
conducted assessing FMT for UC in adults (www.
clinicaltrials.gov).
Crohn’s Disease: FMT a Supporting Role?
The lead author’s experience with treating CD using repeat-
ed FMT dates back to 1988 [36], where a 4-month response
was observed but poorly sustained. A recent pilot study in 4
refractory patients with CD was reported, in whom the TM
was administered via naso-jejunal tube 3 times over a 2-day
period [42]. None had significant clinical or endoscopic
improvement at 8-weeks follow-up. Although minor
changes in microbial composition were observed (weeks 2–
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4), by week 8, all patients had returned to their baseline
microbial composition, suggesting that unlike in CDI, FMT
in these CD patients only transiently implanted at best. FMT
appears more appropriate in CD patients with CDI, where a
measurable clinical improvement can be gauged and CDI
cured (Fig. 2) [23]. Hence, it may be relegated to a support-
ive role in CD.
Irritable Bowel Syndrome
Published use of FMT in irritable bowel syndrome (IBS) is
limited to some 50 case reports in diarrhea-predominant IBS
(D-IBS) [36]. Since that publication, the lead author has treated
with FMT, over 5–14 days, more than 300 D-IBS patients
whose severe symptoms had failed to respond to conservative
measures. Clinical response has been most marked in those
with more severe diarrhea and pain, but results in this group are
not as dramatic or consistent as in CDI. A few reports on the
use of FMT in constipation-predominant IBS are available
[43–45]. While anecdotal reports are encouraging, no con-
trolled trials to date have been performed, and these are re-
quired to validate efficacy and determine whether the GI
microbiota may possess the key for unlocking the etiology
and effective treatment of IBS, as in CDI.
Other Conditions
Other disease states that are closely linked to the GI
microbiota, such as obesity [46, 47], metabolic syndrome
[48], and diabetes mellitus, may potentially be treated by
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Fig. 1 A 33-year-old male with
ulcerative colitis presented with
abdominal pain, bloody diarrhea,
and mucus discharge. Failing
standard antiinflammatory drugs
with frequent relapses, fecal
microbiota transplantation (FMT)
was introduced. FMTwas first
administered via a
transcolonoscopic route followed
by daily enemas, reducing to
twice weekly, weekly, and then
fortnightly. After 80 FMT
infusions, he was passing normal
stool once per day and was off all












Fig. 2 A 14-year-old boy with
Clostridium difficile and severe
Crohn’s ileitis poorly controlled
on prednisone and azathioprine
was treated with fecal microbiota
transplantation, with a total of 60
home infusions. He experienced
marked clinical improvement,
and, incidentally, his severe
facial acne also healed within
7 days. Ileoscopy showed
pronounced improvement in the
inflammation, and Clostridium
difficile infection cure was
confirmed upon stool testing
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FMT in the future. A recent pilot study assessed the effects of
FMT from lean healthy donors to individuals with metabolic
syndrome [49]. Six weeks post-FMT, improved insulin sensi-
tivity was noted in the 9 recipients, along with intestinal
microbiota changes characterized by increased butyrate-
producing bacteria.
Regarding other potential treatable conditions, evidence for
FMT at present is lacking. Isolated case reports of FMT re-
sponse include multiple sclerosis [50], Parkinson’s disease [51],
chronic fatigue syndrome [52], and idiopathic thrombocytope-
nic purpura [53]. Apart from these published reports, the lead
author has also observed convincing improvement after FMT in
several other conditions, including rheumatoid arthritis,
sacroileitis, halitosis, acne, insomnia, and major depression.
Autism spectrum disorder is another condition in which the
GI microbiota is implicated [54], where FMT may have a role.
Unanswered Questions
Despite the enthusiasm and explosion of research activity in
FMT, important questions remain, apart from those address-
ing potential therapeutic indications. These include whether
the TM could be whole flora extract or cultured TM,
methods of administration, implantation success, and immu-
nologic responses, as well as the long-term safety implica-
tions of altering microbiota composition.
Another crucial question is what makes a “good donor”?
The microbiome features of what constitutes a good donor
have not been studied using metagenomics and are unknown.
Would a “good donor” for CDI, for example, constitute a
“good donor” for another indication, or is it a patient-
specific problem where the donor needs to be matched to the
recipient? Seminal studies have demonstrated that variation of
GI microbiota between individuals at a genus and species
level tends to congregate within clusters or enterotypes de-
fined by interactions between members of the microbial com-
munity [55] and dietary influences [56]. The robustness and
predictability of such enterotypes in different cohorts and at
phylogenetic and functional levels indicate that they are the
result of well-balanced, defined microbial community
compositions/host–microbial symbiotic states, of which only
a limited number seem to exist across individuals.
Advances in culture-independent molecular microbiologi-
cal sequencing techniques and powerful bioinformatic pro-
grams are allowing increasingly detailed, efficient, and afford-
able analysis of GI microbiota that will refine our knowledge
of its compositional and functional features [57]. Associated
with this will be an improved understanding of the impact of
FMT on host GI microbiota and the likely therapeutically
active/beneficial microbial components, which in turn will
allow more meticulous and specific selection of suitable do-
nors. That said, while the GI microbiome and FMT are
currently attracting great interest and are very active topical
areas of research with enormous therapeutic potential, there is
a need to proceed with caution [58].
Future Directions of FMT
FMT TM began as crude, homogenized human feces, pre-
sumably dissolved in water or saline and administered as an
enema [2], and similar TM continues to be used currently
[11••]. Refinement of this tissue to a highly filtered, frozen
colonic microbiota was reported to be equally effective to the
crude homogenate by Hamilton et al. [17]. The advantages of
this minimally manipulated human tissue TM include
equipotency in CDI treatment, absence of fecal smell, quan-
tifiable reproducible cellular content, prolonged viability,
and implantation equivalent to the crude homogenate [27•].
Cultured TM, as opposed to a fecal extract, holds some
attraction. Cultured “mini” versions of the complete gut
microbiota have succeeded in treating CDI in animal studies
[59] and a handful of human cases [60, 61]. Lawley et al. [59]
designed a mixture of phylogenetically diverse intestinal bacte-
ria that disrupted intestinal dysbiosis, reestablished health-
associated microbiota, and resolved CDI in mice. Tvede et al.
[60] in 1989 used 10 cultured human fecal bacteria to cure
relapsing CDI in 5 patients. Meanwhile Petrof et al. [61] recent-
ly used a culture comprising 33 species of commensal bacteria
derived from human feces to successfully treat antibiotic refrac-
tory CDI in 2 patients. These are but a few examples of a
multitude of potential human microbiota component mixtures
that could be developed into “mini” versions of the complete
flora and be successful in CDI. Although cultured “mini” ver-
sions give the perception of “purity,” the fecal smell remains. A
further concern is the phenomenon of passaging, by which
progressive reculturing alters original bacterial characteristics
and function and diminishes the capacity to implant, the para-
mount problem of probiotics. More important, only in CDI do
we have a clue of the compositional deficiencies where such
cultured versions may work. In other conditions, such as UC,
where apart from reduced diversity the defect is unclear, it
makes sense to replace with full-spectrum fecal TM to ensure
that any missing components are being replaced. Jorup-
Ronstrom et al. [62] reported treating CDI using amix of human
fecal microbes where the entire stool components have been
recultivated fortnightly for over 10 years under strict anaerobic
conditions, albeit from a single donor. Their success rate of
69 % is less than standard FMT and demonstrates that whole
stool culture is possible but that passaging may already be
showing loss of efficacy over time in spite of the TM compris-
ing a vast number of subspecies of microbes.
The future TM from all these research efforts may well be
the use of lyophilized, encapsulated, and enteric-coated cap-
sules to allow oral administration. Ultimately, it is conceivable
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that after any use of antibiotics, oral FMTwill become routine
for ecologically conserving our GI microbiome.
Conclusion
FMT has undergone a rapid transformation in the past decade,
from being considered an evidence-free, alternative form of
medicine to acceptance as a mainstream treatment option with
vast therapeutic potential. While now proven as the most effec-
tive therapy for R-CDI, controlled data are lacking with regard
to its role in other conditions associated with GI dysbiosis, and
high-quality clinical trials are required in these areas.
Additionally, further research is required to refine optimal tissue
or product composition, as well as mode of FMT administra-
tion. Further work will follow in defining the dysbiosis in
numerous conditions and in obtaining a greater understanding
of the complex microbiological changes after FMT therapy,
searching for potential long-term benefits and adverse effects.
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